Solid Tumor, Adult trials recruiting in Florida
All Solid Tumor, Adult trials nationally
19
Recruiting in Florida
9
Cities with sites
Cities in Florida
Tampa 7Jacksonville 6Miami 3Orlando 3Lake Mary 2Boca Raton 1Fort Myers 1Plantation 1Weston 1
Recruiting trials in Florida
- A Beta-only IL-2 ImmunoTherapY Study
- A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
- A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- A Study of VET3-TGI in Patients With Solid Tumors
- A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Intravital Microscopy in Human Solid Tumors
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- PRE-ISPY Phase I/II Oncology Platform Program
- Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors